A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
Inclusion criteria:
Exclusion criteria:
Participate-In-This-Study1@its.jnj.com844-434-4210
Wichita, Kansas 67214, United States
Sterling Heights, Michigan 48314, United States
Saint Louis Park, Minnesota 55426, United States
Saint Paul, Minnesota 55101, United States
Mineola, New York 11501, United States
New York, New York 10016, United States
Pittsburgh, Pennsylvania 15232, United States
Santo André, 09060 870, Brazil
Victoria, British Columbia V8R 6V5, Canada
Localita La Schiana Pozzuoli, 80078, Italy
Torino, 10126, Italy
Sunto Gun, 411 8777, Japan
Newcastle upon Tyne, NE7 7DN, United Kingdom
Preston, PR2 9HT, United Kingdom